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REVIEW
Abstract: Irritable bowel syndrome with constipation (IBS-C) as the predominant bowel
symptom is a prevalent disorder, characterized by recurring abdominal pain/discomfort,
bloating, and constipation, and imposes a significant socio-economic burden. Traditional
treatments generally address just one of the multiple IBS symptoms. The efficacy and safety
profile of tegaserod, a serotonin 5-HT4 receptor agonist, has been demonstrated in several
randomized, placebo-controlled, and open-label trials. This review discusses the major clinical
trials of tegaserod, which have involved 8948 IBS patients. Overall, data reveal that tegaserod
is an effective treatment for IBS-C, providing statistically significant relief of overall and
multiple individual IBS-C symptoms (abdominal pain/discomfort, bloating, and constipation)
in both placebo-controlled and “real-life” open-label settings. Repeat treatments with tegaserod
were also shown to be effective, which is noteworthy given the chronic and episodic nature of
IBS. Moreover, tegaserod was associated with improvements in patients’ quality of life and
work productivity. Data also indicate that tegaserod is well tolerated over the short-term (4
weeks), long-term (12 months), and repeated treatments. Diarrhea is the only adverse event
consistently associated with tegaserod and was generally mild and transient. Overall, tegaserod
has been demonstrated to offer effective and well-tolerated treatment of IBS-C, providing
patients with meaningful symptom relief.
Keywords: efficacy, IBS, safety, serotonin, tegaserod, Zelnorm
Introduction
Prevalence and impact of IBS
Irritable bowel syndrome (IBS) is a chronic and episodic gastrointestinal (GI) disorder.
Cardinal symptoms include abdominal pain/discomfort, bloating, and altered bowel
function, with the predominant bowel symptom determining the subclassification of
IBS: IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), or IBS with
alternating symptoms of constipation or diarrhea (IBS-A). To date, no structural or
specific biochemical markers have been identified for IBS and, therefore, its diagnosis
is based on the recognition of key symptoms and exclusion of organic disease
(Malagelada 2006). Several diagnostic guidelines have been established for IBS,
including the Rome II criteria (Thompson et al 1999). Rome II criteria classify IBS
as abdominal pain/discomfort associated with two out of three of the following
features: relief with defecation, onset associated with a change in stool frequency
(<3 bowel movements per week or >3 bowel movements per day) and/or onset
associated with a change in stool form (lumpy/hard or loose/watery stool), occurring
for at least 12 weeks (not necessarily consecutive) in the preceding 12 months
(Thompson et al 1999).
IBS is a common disorder, thought to affect approximately 10%–15% of
individuals in Western countries (Hungin et al 2003, 2005). In addition, IBS is
Tegaserod in the treatment of irritable bowel






1Department of Internal Medicine,
Israelitisches Krankenhaus, Hamburg,
Germany; 2Clinical Development,
Novartis Pharma GmbH, Nuremberg,
Germany
Correspondence: Peter Layer
Professor of Medicine, Medical Director,
Israelitic Hospital, Academic Hospital,
Hamburg University, Orchideenstieg 14,
D 22297 Hamburg, Germany
Tel: +49 40 5112 5211
Fax: +49 40 5112 5227
Email: layer@ik-h.deTherapeutics and Clinical Risk Management 2007:3(1) 108
Layer et al
detrimental to patients’ quality of life (QoL), affecting their
daily routines, social lives, and emotional well-being (Hahn
et al 1999; Gralnek et al 2000; Frank et al 2002). IBS also
has a major economic impact on society due to its prevalence
and the chronic and recurring nature of the symptoms.
Studies have demonstrated that the total direct costs of IBS
are similar to those of Alzheimer’s disease, asthma, and
migraine (Kozma et al 2002; Müller-Lissner and Pirk 2002).
Given the prevalence and substantial socioeconomic impact
of IBS, it is essential that effective and well-tolerated
treatments are available.
Current treatment options for IBS
Traditional pharmacological treatments
To date, there is no cure for IBS and so treatments are based
on alleviating one or more of the multiple symptoms. A
number of traditional pharmacological treatments are
commonly used, including laxatives, antidiarrheal agents,
antispasmodics, and low-dose antidepressants. Overall,
these agents may be considered as suboptimal treatments
for IBS since they each focus on just one symptom of this
disorder (ie, constipation, diarrhea, or abdominal pain/
discomfort), leaving other symptoms untreated. For
example, the antidiarrheal agent, loperamide, has been
demonstrated to be effective for diarrhea, but does not reduce
other or overall symptoms of IBS (Brandt et al 2002;
Lesbros-Pantoflickova et al 2004). Consequently, patients
may have to take several different medications to address
their multiple symptoms. Furthermore, although these agents
are often used as first-line treatments for IBS, evidence for
their efficacy is limited. This is due, in part, to a lack of
randomized, controlled clinical trials or inadequate trial
design, as highlighted by several reviews of clinical trials
for IBS treatments (Brandt et al 2002; Lesbros-Pantoflickova
et al 2004; Valenzuela et al 2004; Quartero et al 2005).
Along with efficacy, safety and tolerability are important
issues for IBS pharmacologic therapies, as patients are likely
to require long-term and repeated treatment. However,
conventional IBS therapies can cause side effects that mimic
or exacerbate other IBS symptoms. For example, bulking
laxatives may increase bloating and abdominal pain/
discomfort in some IBS patients, while some tricyclic
antidepressants and antispasmodics may cause constipation
(Brandt et al 2002).
Serotonergic agents
In addition to traditional pharmacotherapies, serotonergic
agents are also used to treat IBS symptoms. Serotonin is a
key neurotransmitter in the GI tract, where it is released in
response to changes in luminal pressure or content of the
small intestine. Serotonin stimulates the release of other
neurotransmitters and together these influence intestinal
peristalsis, secretion of water, and visceral sensation
(Gershon 1999, 2004; Crowell 2004). Recent findings
suggest that patients with IBS have abnormalities in the
synthesis and function of serotonin in the GI tract (Coates
et al 2004; Camilleri 2005). This is thought to lead to the
key symptoms of IBS, such as abdominal pain/discomfort
and altered bowel motility.
Alosetron and cilansetron are serotonergic agents with
serotonin type 3 (5-HT3) receptor antagonist actions, while
cisapride has a mixed 5-HT3 antagonist/5-HT4 receptor
agonist action. Alosetron has been shown to relieve global
and individual symptoms of IBS-D (Brandt et al 2002;
Lesbros-Pantoflickova et al 2004; Valenzuela et al 2004;
Quartero et al 2005), but has been associated with severe
constipation and ischemic colitis and, since June 2002, the
US Food and Drug Administration (FDA) restricted its
license to women with severe IBS-D who fail to respond to
other therapies. Cilansetron is currently in clinical
development as a treatment for IBS-D, although it may also
be associated with an increased incidence of ischemic colitis.
Regulatory bodies have requested further clinical trials be
conducted before they will consider licensing this treatment.
Some, but not all, studies demonstrate that cisapride
improves individual symptoms of IBS-C, including
constipation and abdominal pain/discomfort. However,
following reports of serious cardiac side effects unrelated
to the 5-HT3 antagonist/5HT4 receptor agonist actions,
cisapride is only available to patients who meet strict
inclusion criteria in limited countries (Ferriman 2000; Wang




Pharmaceuticals Inc) has a different mode of action to
alosetron and cisapride. It acts as a serotonin 5-HT4 receptor
agonist, and is without 5-HT3 antagonistic properties or
affinity for dopamine receptors (Pfannkuche et al 1995).
Tegaserod is structurally similar to serotonin except it is
more polar, which minimizes its potential to cross the blood–
brain barrier. Preclinical and clinical studies reveal that
tegaserod can facilitate GI motility and intestinal secretion
and reduce visceral sensitivity, thereby increasing the
frequency of bowel movements, softening stools, and
reducing abdominal pain/discomfort (Fioramonti et al 1998;
Grider et al 1998; Jin et al 1999; Schikowski et al 1999;
Stoner et al 1999; Prather et al 2000; Degen et al 2001;Therapeutics and Clinical Risk Management 2007:3(1) 109
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Coffin et al 2003; Sabate et al 2005). Recent reviews of
clinical trial data suggest that tegaserod effectively relieves
individual and global symptoms of IBS-C and has a
favorable safety profile (Brandt et al 2002; Lesbros-
Pantoflickova et al 2004; Valenzuela et al 2004; Schoenfeld
2005).
The aim of this paper is to review tegaserod as a treatment
for IBS-C with particular focus on clinical trial data. The
trials discussed in depth are divided into the four pivotal
phase III trials involving 5859 IBS patients, three of which
were the basis of FDA approval of tegaserod as a treatment
for IBS-C, and six additional phase IIIb/IV trials involving
3089 IBS patients, which include open-label, repeat
treatment studies to reflect “real-life” clinical practice. Data
on the safety and tolerability of tegaserod following short-
and long-term treatment are also discussed, along with
special safety considerations.
Pivotal phase III clinical trials of
tegaserod
Trial designs
The tegaserod clinical trial program includes four pivotal
trials, which were conducted throughout 26 countries
(Lefkowitz et al 1999; Müller-Lissner et al 2001; Novick et
al 2002; Tack et al 2005). They employed randomized,
multicenter, double-blind, placebo-controlled designs and
each involved large numbers of IBS-C patients (Table 1).
All the pivotal trials incorporated a treatment-free
baseline period, during which IBS-C symptoms were
assessed. This was followed by a 12-week treatment period
in Studies 1–3 (Lefkowitz et al 1999; Müller-Lissner et al
2001; Novick et al 2002) and a withdrawal period in Study
3 only (Novick et al 2002). The primary efficacy variable
for Studies 1–3 was Subject’s Global Assessment (SGA) of
Relief (Lefkowitz et al 1999; Müller-Lissner et al 2001;
Table 1 Overview of the design of the pivotal trials of tegaserod in IBS-C patients
Study 1 Study 2 Study 3 ZENSAA
(Müller-Lissner et al (Lefkowitz et al 1999) (Novick et al 2002) (Tack et al 2005)
2001)
Location Europe, South Africa, USA North and South America USA Europe, North and South
America, South Africa
Design • 4-week baselinea • 4-week baselinea • 4-week baselinea • 2-week baselinea
• 12-week treatment • 12-week treatment • 12-week treatment • Two 4-week treatment
• 4-week withdrawal
a periods separated by
treatment-free interval
Treatment
b Tegaserod 6 mg bid Tegaserod 6 mg bid Tegaserod 6 mg bid Tegaserod 6 mg bid
Tegaserod 2 mg bid Tegaserod 2 mg bid Placebo Placebo
Placebo Placebo
Patients
c 881 men and women 799 men and women 1519 women only 2660 women only
Primary outcome variable
d SGA of Relief SGA of Relief SGA of Relief • Satisfactory relief of
overall IBS symptoms
• Satisfactory relief of
abdominal discomfort/pain
Secondary outcome • SGA of Abdominal • SGA of Abdominal • SGA of Abdominal • Effect on:
variables
e Pain/Discomfort Pain/Discomfort Pain/Discomfort - Abdominal 
• Effect on: • Effect on: • SGA of Bowel Habit discomfort/pain
- Abdominal - Abdominal • SGA of Satisfaction - Bloating
discomfort/pain discomfort/pain with Bowel Habit - Stool frequency
- Bloating - Bloating • Effect on: - Stool consistency
- Stool frequency - Stool frequency - Abdominal - Overall satisfaction
- Stool consistency - Stool consistency discomfort/pain with treatment
- Bloating • IBS-QOL, EQ-5D,
- Stool frequency WPAI:IBS-C





cPatients fulfilled Rome I (Studies 1–3) or Rome II (ZENSAA) criteria for IBS-C; 
dPatient’s assessment; 
eAssessed
using ordinal scales. Patients had broadly similar demographic characteristics and baseline symptoms between the four studies.
Abbreviations: bid, twice daily; EQ-5D, EuroQoL; IBS, irritable bowel syndrome; IBS-QOL, IBS-specific quality of life; WPAI: IBS-C, Work productivity activity
impairment for IBS with constipation; SGA, Subject’s Global Assessment, measured by a patient’s response to the question “Please consider how you felt this last
week in regard to your IBS, in particular your overall well-being and symptoms of abdominal pain/discomfort and altered bowel habit.” Compared with baseline,
patients rated their symptoms on a 5-point scale: completely relieved, considerably relieved, somewhat relieved, unchanged, or worse.Therapeutics and Clinical Risk Management 2007:3(1) 110
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Novick et al 2002). This is an important outcome variable
due to the varying importance that patients place on their
different IBS symptoms (Dunger-Baldauf et al 2003).
Responders were patients whose symptoms were
“completely relieved” or “considerably relieved” at least
50% of the time or “somewhat relieved” 100% of the time
during the final 4 weeks of the study. Patients also assessed
their individual IBS symptoms as secondary efficacy
variables (Table 1).
IBS patients often require repeat courses of therapy due
to the chronic and episodic nature of their symptoms and,
as recommended by the European Committee for Medicinal
Products for Human Use (CHMP; formally known as the
Committee for Proprietary Medicinal Products [CPMP]), it
is important that treatment can be repeated without loss of
efficacy (CPMP 2003). Therefore, Study 4 (ZENSAA,
Zelnorm in Europe, North and South America and Africa)
investigated the effects of repeat tegaserod treatment.
Patients who responded to initial treatment (4 weeks) entered
a treatment-free interval. Patients were randomized to
receive a further 4 weeks of either tegaserod or placebo if
their symptoms recurred during this interval. The ZENSAA
trial utilized two primary efficacy variables: whether patients
experienced satisfactory relief of their overall IBS
symptoms, and whether patients experienced satisfactory
relief of their abdominal discomfort/pain during the last
week (yes/no). Responders were patients with satisfactory
relief during at least 3 weeks of each 4-week treatment cycle
(Tack et al 2005). Effects of treatment on individual IBS
symptoms were also assessed, along with patients’ QoL and
work productivity, examined via IBS-QOL (IBS-specific
QoL), EQ-5D (EuroQoL) and WPAI:IBS-C (Work
Productivity Activity Impairment for IBS-C) questionnaires,
along with their overall satisfaction with treatment (Table
1).
Efficacy data
Data from all four trials reveal that tegaserod was
consistently and significantly better than placebo at relieving
overall and key individual IBS symptoms (Lefkowitz et al
1999; Müller-Lissner et al 2001; Novick et al 2002; Tack et
al 2005). The main findings from each of the pivotal trials
are summarized in Table 2.
In Studies 1–3, tegaserod provided significantly greater
relief of overall IBS symptoms during nearly all weeks of
treatment compared with placebo (p<0.05, Figure 1)
(Lefkowitz et al 1999; Müller-Lissner et al 2001; Novick et
al 2002). Tegaserod also significantly improved individual
IBS symptoms, including abdominal pain/discomfort,
bloating, and constipation (increased stool frequency and
Table 2 Overview efficacy findings of the pivotal trials of tegaserod in IBS-C patients
Primary efficacy variables
a Secondary efficacy variables
Study 1 • Greater SGA of relief of overall IBS • Greater improvements in abdominal
(Müller-Lissner et al 2001)  symptoms for 11 out of 12 weeks pain/discomfort, stool frequency, stool consistency
(tegaserod vs placebo, p≤0.05) during most weeks (tegaserod vs placebo, p<0.05)
• At endpoint, treatment difference • Favorable trend for tegaserod reducing the number
from placebo was 11.8% and 12.7% of days with bloating
for 2 mg and 6 mg tegaserod,
respectively
Study 2  • Greater SGA of overall relief at • Improved abdominal pain/discomfort, bloating, stool
(Lefkowitz et al 1999) Months 1 and 2 (tegaserod vs placebo, frequency, and stool consistency (tegaserod vs
p<0.05), but not at study endpoint  placebo, p<0.05)
Study 3 • Greater SGA of relief of overall IBS • Improved SGAs of abdominal pain/discomfort, bowel
(Novick et al 2002) symptoms for 11 out of 12 weeks habit and satisfaction with bowel habit, and
(tegaserod vs placebo, p≤0.05) symptoms of bloating, stool frequency, stool
•  At endpoint, treatment difference consistency and days with straining (tegaserod vs
between tegaserod and placebo was 4.7% placebo, p<0.05)
ZENSAA • More tegaserod than placebo responders
a • Greater relief during initial and repeated treatment
(Tack et al 2005) during initial and repeat treatment for from abdominal discomfort/pain, bloating, and
satisfactory relief of overall IBS symptoms: improvements in stool frequency and stool
33.7% vs 24.2%, 44.9% vs 28.7%; and relief consistency (tegaserod vs placebo, p≤0.001)
of abdominal discomfort/pain: 31.3% • Greater treatment satisfaction, work productivity
vs 22.1%, 42.4% vs 27.1%; all p<0.0001) and improvements in QoL (tegaserod vs placebo,
p<0.05)
Notes: 
aResponders had satisfactory relief of their overall IBS symptoms for at least 3 out of the 4 weeks in each treatment cycle.
Abbreviations: IBS-C, irritable bowel syndrome with constipation; SGA, Subject’s Global Assessment; QoL, quality of life.Therapeutics and Clinical Risk Management 2007:3(1) 111
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softened stools) compared with placebo (Lefkowitz et al
1999; Müller-Lissner et al 2001; Novick et al 2002). After
withdrawal of treatment, IBS symptoms returned rapidly,
but did not reach baseline levels (Novick et al 2002).
In the ZENSAA trial, tegaserod treatment was associated
with significantly more responders for relief of overall IBS
symptoms (Figure 1) and relief of abdominal discomfort/
pain compared with placebo (p<0.0001). This occurred
during both initial and repeat treatments (Tack et al 2005).
Similar to the other pivotal studies, tegaserod was also
superior to placebo for relief of individual IBS symptoms,
including bloating and constipation, following initial and
repeat treatments (p≤0.001). Furthermore, during both
treatment cycles, more patients expressed overall satisfaction
with tegaserod compared with placebo (56.2% vs 41.2%;
66.1% vs 50.1%, both p<0.0001) (Tack et al 2005). Similar
to Study 3, IBS symptoms recurred gradually following
cessation of treatment, with no evidence of a rebound effect
(Tack et al 2005). Overall, these findings suggest that many
patients who benefit from an initial course of tegaserod
treatment are likely to benefit from a further course, should
their symptoms recur (Tack et al 2005). It is noteworthy
that no other IBS treatments have been shown to effectively
address bloating, which is one of the symptoms IBS patients
report as most bothersome (Schmulson et al 1999; Bijkerk
et al 2003).
In the ZENSAA trial, the positive effect of tegaserod on
IBS symptom relief was mirrored by significant
improvements in QoL and health economic-related
outcomes. In tegaserod-treated patients, IBS-QOL scores
were significantly higher in five out of the eight domains
(dysphoria, body image, health worry, food avoidance, and
impact on relationships; p<0.05) compared with placebo
(Patrick et al 2005; Tack et al 2005). Less presenteeism
(impairment while at work), absenteeism (work time
missed), and overall work productivity loss were also
observed in tegaserod than placebo patients (p<0.0001),
equating to an increase of 2.5 hours’ work productivity per
week (Reilly et al 2005; Tack et al 2005).
In all four pivotal trials, response to tegaserod was rapid
and sustained. For each of the variables, response occurred
within the first week of treatment (illustrated for stool
frequency in Figure 2) and continued throughout the
treatment period (illustrated for abdominal pain/discomfort
in Figure 3), with no evidence of tachyphylaxis (Lefkowitz
et al 1999; Müller-Lissner et al 2001; Novick et al 2002;
Tack et al 2005). Moreover, the response rate for tegaserod
tended to increase during the course of treatment (Figure
4). These data indicate that patients who do not respond to
tegaserod during the first few weeks of treatment may go
on to respond a few weeks later if treatment is continued.
The placebo effect (a response to a pharmacologically
inactive therapy) is well documented in trials of patients
with functional bowel diseases (Patel et al 2005). Estimates
of response to placebo in IBS trials are typically between
40% and 70%, making it difficult to detect a therapeutic
gain with active treatment (Patel et al 2005). However, it is
noteworthy that in each of the four key tegaserod IBS trials,
a statistically significant greater response to treatment was
observed for tegaserod compared with placebo. For overall
symptom relief, response above placebo for tegaserod
ranged between 4.7% and 16.2% (Lefkowitz et al 1999;
Müller-Lissner et al 2001; Novick et al 2002; Tack et al
2005). Numbers needed to treat (NNT) to derive benefit
Figure 1 Subject’s Global Assessment (SGA) of Relief demonstrates consistent
improvement across tegaserod clinical trials.
Note: ***p<0.001.
Abbreviations: P1, first treatment cycle; P2, second treatment cycle.
Figure 2 Rapid onset of action with tegaserod: increased number of bowel
movements. Pooled data from Studies 1 and 2 (Leftkowitz et al 1999; Müller-
Lissner et al 2001; Novartis. Data on file).
Note: *p<0.05 vs placebo (change from baseline score).Therapeutics and Clinical Risk Management 2007:3(1) 112
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calculated for women aged ≤65 years in the pivotal trials
were 5.6, 6.8, and 7.0 for Studies 1, 2, and 3, respectively,
based on the definition of responder (patients whose
symptoms were “completely relieved” or “considerably
relieved” at least 50% of the time or “somewhat relieved”
100% of the time during the final four weeks of the study).
NNT for Study 4 was 10.8 and 6.0 for initial and repeated
treatment respectively, based on the definition of responder
(patients with satisfactory relief during at least 3 weeks of
each 4-week treatment cycle) (Novartis. Data on file).
Further phase IIIb/IV clinical trials
of tegaserod in IBS-C
The aim of these six phase IIIb/IV studies was to further
assess tegaserod treatment in IBS patients of differing race
and culture from a wide range of countries (Kellow et al
2003; Uscanga-Dominguez and Cohen Munoz 2003;
Bardhan et al 2004; Nyhlin et al 2004; Layer et al 2005;
Müller-Lissner et al 2005). While two of these trials followed
similar randomized, placebo-controlled designs to the
pivotal IBS trials, the others were open-labeled and designed
to evaluate the effectiveness of tegaserod under real-life
conditions (Table 3).
Data from the two randomized, placebo-controlled trials
(Kellow et al 2003; Nyhlin et al 2004) were consistent with
the four pivotal trials (Lefkowitz et al 1999; Müller-Lissner
et al 2001; Novick et al 2002; Tack et al 2005). They
demonstrated that significantly more patients taking
tegaserod than placebo experienced satisfactory relief of
their overall IBS symptoms and greater improvements in
individual symptoms, including abdominal pain/discomfort,
stool frequency, stool consistency, and straining during
defecation. These results confirm that tegaserod is an
effective treatment for overall and individual symptoms of
IBS, irrespective of factors such as geographical region,
race, and culture. In addition, as two of these trials were
conducted in IBS patients excluding those with diarrhea
(non-IBS-D), they also indicate that tegaserod is effective
in this subgroup of patients, as well as those diagnosed with
IBS-C according to Rome II criteria.
Three of the phase IIIb/IV studies investigated the effects
of repeated tegaserod treatment (Uscanga-Dominguez and
Cohen Munoz 2003; Bardhan et al 2004; Müller-Lissner et
al 2005). These were open-label studies and are more likely
to reflect clinical practice than placebo-controlled trials. In
the UK and Latin American retreatment studies, patients
who responded to initial tegaserod therapy (satisfactory
relief of overall IBS symptoms for at least 2 out of 4 weeks’
treatment) were randomized to either continue on tegaserod
or withdraw from treatment. In both studies, almost 60%
more patients who withdrew from tegaserod experienced
symptom recurrence compared with those who continued
therapy (p<0.0001) (Uscanga-Dominguez and Cohen
Munoz 2003; Bardhan et al 2004) (Table 3). A significant
treatment benefit for abdominal pain/discomfort, bloating
(both p≤0.02) (Uscanga-Dominguez and Cohen Munoz
2003; Bardhan et al 2004), stool frequency, and overall
symptom relief (both p<0.0004) was observed in patients
who continued tegaserod treatment compared with those
who withdrew (Uscanga-Dominguez and Cohen Munoz
Figure 3 Sustained effect of tegaserod: improved abdominal pain and discomfort.
Study 1. Copyright © 2001. Figure adapted with permission from the Blackwell
Publishing Group from Müller-Lissner SA, Fumagalli I, Bardhan KD, et al. 2001.
Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel
syndrome patients with abdominal pain, bloating and constipation.  Aliment
Pharmacol Ther, 15:1655-66.
Note: 6-point scale: 0 = absent to 5 = very severe; *p<0.05 vs placebo (change
from baseline score).
Figure 4 Subject’s Global Assessment (SGA) of Relief during tegaserod
treatment. Study 1. Copyright © 2001. Figure reproduced with permission from
the Blackwell Publishing Group from Müller-Lissner SA, Fumagalli I, Bardhan KD,
et al. 2001. Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in
irritable bowel syndrome patients with abdominal pain, bloating and
constipation.  Aliment Pharmacol Ther, 15:1655-66.
Note: *p<0.05 vs placebo.Therapeutics and Clinical Risk Management 2007:3(1) 113
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2003). In the German retreatment study, withdrawal of
tegaserod resulted in symptom recurrence in the majority
of patients (83.9%), while retreatment of responders to initial
therapy, following symptom recurrence, was effective in
over 90% of patients. Similar improvements from baseline
in symptoms of abdominal pain, bloating, stool frequency
and consistency were also observed following both the initial
(p≤0.0003) and repeated treatments with tegaserod (Müller-
Lissner et al 2005).
A second open-label study conducted in Germany
investigated the effectiveness of tegaserod in “real-life”
primary care settings, focusing on patients with mild or
moderate IBS (Layer et al 2005). Response rates for overall
IBS symptom relief (satisfactory relief of IBS symptoms
Table 3 Overview of the design and key efficacy outcomes of the additional Phase IIIb/IV trials of tegaserod in IBS patients
Study characteristics
Patientsa Study design Key findings
ZAP n=520 (non-IBS-D) RCT • More tegaserod than placebo respondersb over
(Kellow et al 2003) Asia–Pacific countries • 2-week baseline Weeks 1–4 (56% vs 35%) and Weeks 1–12 (62% vs
• 12 weeks’ treatment 44%; p<0.0001)
(tegaserod 6 mg bid or • Greater reductions in days without bowel
placebo) movements, hard/very hard stools, straining,
• 4-week withdrawal sensation of incomplete evacuation for tegaserod vs
placebo (p<0.05), but not for abdominal pain
TENOR n=647 (non-IBS-D) RCT • More tegaserod than placebo responders
b (54% and
(Nyhlin et al 2004) Nordic countries • 2-week baseline 78% higher for Weeks 1–4 and Weeks 1–12,
• 12 weeks’ treatment respectively; p<0.005) 
(tegaserod 6 mg bid or • Greater reductions in days without bowel
placebo) movements, hard/very hard stools, straining,
• 4-week withdrawal sensation of incomplete evacuation for tegaserod vs
placebo patients (p<0.05), but not for abdominal
pain/discomfort and bloating
German retreatment n=513 (IBS-C
c) Open-label • 85% were respondersb in first treatment cycle
(Müller-Lissner et al 2005) Germany • 2-week baseline  • Recurrence of symptoms in 83.9% after a mean of
• 12 weeks’ treatment 38 days without treatment
(tegaserod 6 mg bid) • 89.3% were responders
b during retreatment
• 8-week withdrawal 
• 4 weeks’ treatment
(tegaserod 6 mg bid)
UK retreatment n=519 (IBS-C
c) Open-label, randomized • Shorter time to symptom recurrence in withdrawal
(Bardhan et al 2004) UK • 4-week baseline  vs tegaserod patients. More tegaserod patients
• 4 weeks’ treatment without symptom recurrence by Week 8 vs patients
(tegaserod 6 mg bid) on intermittent (86.5% vs 58.1%) or withdrawal of
• 8-week withdrawal or treatment (69.2% vs 11.3%, p<0.0001) 
maintenance of tegaserod • Significant reductions for bloating (p<0.01) and
6 mg bid abdominal pain/discomfort (p<0.02) 
LATAM  n=678 (IBS-Cc) Open-label, randomized • 82% experienced overall symptom relief
(Uscanga-Dominguez Latin America • 2-week baseline • Lower  symptom  recurrence in patients remaining
and Cohen Munoz • 4 weeks’ treatment on tegaserod vs those withdrawn (10% vs 67%,
2003) (tegaserod 6 mg bid) p<0.0001) 
• 10-week withdrawal or
maintenance of tegaserod
6 mg bid 
German primary care n=212 (IBS-C)  Open-label • Response rates
b: 64.2% at Week 4, 70.3% at
(Layer et al 2005) Germany • 2-week baseline  Week 12 
• 12 weeks’ treatment • After 12 weeks, significant reductions in abdominal
(tegaserod 6 mg bid) pain/discomfort and bloating (p<0.0001) and
• 9-month optional treatment improvements in stool frequency and stool
extension (tegaserod consistency (p<0.0001) 
6 mg bid)
Notes: aMen and women; bResponders had satisfactory relief of their overall IBS symptoms for at least 2 out of the 4 preceding weeks; cIBS-C classified according to
Rome II criteria.
Abbreviations: bid, twice daily; IBS-D, irritable bowel syndrome with diarrhea; RCT, randomized, controlled trial; IBS-C, irritable bowel syndrome with constipation.Therapeutics and Clinical Risk Management 2007:3(1) 114
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for 2 out of 4 of the previous weeks) increased during
treatment and by Week 12, there were significant
improvements in abdominal pain/discomfort, bloating, stool
frequency, and consistency from baseline (p<0.0001) (Layer
et al 2005).
In summary, findings from these clinical trials
demonstrate that tegaserod is an effective treatment for IBS.
Tegaserod is associated with significant relief, compared
with placebo or baseline, of overall and individual symptoms
of IBS, in IBS-C and non-IBS-D patients from a wide range
of countries throughout the world. Repeated use of tegaserod
is effective, particularly in patients who previously
responded to treatment.
Safety and tolerability of
tegaserod: data from IBS clinical
trials
Safety and tolerability were studied extensively throughout
the tegaserod IBS clinical trial program. All reported adverse
events (AEs) and serious adverse events (SAEs) were
considered, alongside outcomes of physical examinations,
standard hematology and biochemistry testing, urinalysis,
blood pressure, and electrocardiogram (ECG) evaluations.
The available data demonstrate that tegaserod has a
favorable safety profile and is well tolerated by IBS-C
patients. Overall, the incidences of AEs and SAEs were
comparable between patients who received tegaserod or
placebo, with the exception of diarrhea, which was more
frequent in patients taking tegaserod. A meta-analysis of
three IBS-C trials of tegaserod revealed that diarrhea
occurred in 10.0% and 4.2% of tegaserod and placebo
patients, respectively, and was rated as severe in 3.1% and
0.9% of patients (Earnest et al 2002). Diarrhea is an
anticipated AE associated with tegaserod use, given its
promotile activity in the GI tract. In most cases diarrhea
was experienced as a single episode, was mild and transient,
and resolved without the need to interrupt the study drug or
provide therapeutic intervention (Hasler and Schoenfeld
2004). The incidence of serious consequences of diarrhea,
such as hypovolemia, hypotension, and syncope, was very
rare, occurring in 3 out of 9267 patients (0.03%) who
participated in phase II and III trials of tegaserod across all
indications (Novartis. Data on file).
Along with diarrhea, headache was also one of the most
frequently reported AEs in these trials. The effect of
tegaserod on headache is inconclusive since the incidence
was similar in tegaserod and placebo-assigned patients in
some studies (30.6% vs 27.3% [Müller-Lissner et al 2001]
and 12.0% vs 11.1% [Kellow et al 2003] for tegaserod and
placebo patients, respectively) but was more frequent with
tegaserod in others (9.0% vs 5.7% [Novick et al 2002] and
8.0% vs 4.7% [Nyhlin et al 2004]). Other safety data from
these trials indicated that no clinically relevant abnormalities
in hematology, biochemistry, or ECG parameters were
associated with tegaserod treatment.
Figure 5 shows a pooled analysis of AEs leading to
discontinuation from the three pivotal IBS-C trials of 12
weeks’ treatment duration (Studies 1–3) (Lefkowitz et al
1999; Müller-Lissner et al 2001; Novick et al 2002). Similar
to overall AEs, the incidence of AEs leading to study
discontinuation was comparable for tegaserod and placebo
patients, with the exception of diarrhea and headache.
Overall, 1.6% of patients taking tegaserod discontinued from
the studies due to diarrhea compared with 0.3% of patients
taking placebo (p<0.05), and slightly more tegaserod
patients also discontinued due to headache (1.0% and 0.8%
of patients in the tegaserod and placebo groups,
respectively). Tegaserod was also well tolerated in the repeat
tegaserod treatment studies (Müller-Lissner et al 2005; Tack
et al 2005). The AEs observed during initial and repeat
treatment were comparable, while there was a tendency for
their frequency to be lower upon repeat treatment (Table 4)
(Tack et al 2005).
Two studies were also conducted to assess the long-term
safety and tolerability of tegaserod, given that patients may
require treatment for prolonged periods. Both were open-
label, multicenter studies, recruiting patients from primary
care or out-patient centers and comprised either 12 months
of continuous tegaserod treatment (Tougas et al 2002) or
12 weeks of treatment with an optional 9-month extension
(Layer et al 2005). In the first study, 567 patients received
tegaserod and approximately half (52.5%) completed 12
months of treatment. The most common AEs reported reflect
those observed in the short-term IBS trials (mild and
transient diarrhea [10.1%], headache [8.3%], and abdominal
pain [7.4%]). Only one SAE (abdominal pain) was reported
as possibly related to tegaserod, and diarrhea was the most
common reason for discontinuation (3.5%) (Tougas et al
2002). Safety data from the second study were similar, also
reflecting findings in the placebo-controlled trials. Overall,
78.3% of patients completed the initial 12 weeks of
tegaserod and 70.8% completed the 9-month extension
period. Headache and diarrhea were the most commonly
reported AEs in the 12-week phase (13.2% and 9.4%,
respectively), while diarrhea was the third most frequentTherapeutics and Clinical Risk Management 2007:3(1) 115
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AE in the 9-month extension phase, being reported by 7.5%
of patients.
Overall, these data indicate that tegaserod is well
tolerated by patients with IBS-C during short- and long-
term treatment as well as repeat treatment. With the
exception of diarrhea, which was generally mild and
transient and resolved without the need for additional
therapy, and possibly headache, the incidence of AEs was
similar in tegaserod- and placebo-treated patients.
Special safety considerations:
ischemic colitis
Recently, concerns have been raised regarding the potential
risk of ischemic colitis associated with some serotonergic
agents. This follows reports that patients taking alosetron
and cilansetron have a higher incidence of ischemic colitis
than patients taking placebo. These reports showed an
incidence of ischemic colitis of 1.1 case per 1000 patient–
years and 3.77 cases per 1000 patient–years for alosetron-
and cilansetron-treated patients, respectively, which is much
higher than that observed in IBS patients in general (43–48
cases per 100 000 patient–years) (Brinker et al 2004; Singh
et al 2004; Chey et al 2005; Chey and Cash 2005).
In contrast to alosetron and cilansetron, which have a
different mechanism of action to tegaserod, no cases of
ischemic colitis have been reported in tegaserod-treated
patients in the clinical trial program, which includes over
14 000 patients, equivalent to 4888 patient–years of
exposure (Shetzline et al 2005). In addition, a review of
post-marketing data reveals that the incidence of ischemic
colitis in patients who have used tegaserod is comparable
with, if not lower (8 cases per 100 000 patient–years) than,
the incidence observed in the general IBS population
(Shetzline et al 2005).
Special safety considerations:
cardiac safety
Cisapride has been associated with fatal ventricular
arrhythmias via a mechanism unrelated to its serotonergic
action. This resulted in the suspension of its UK license,
restricted license in several countries, and its withdrawal
from the US market. This consequently has heightened
interest in the cardiac safety of other serotonergic agents
(Ferriman 2000; Wang et al 2001; Barbey et al 2002). In
contrast to cisapride, tegaserod has a favorable cardiac safety
Table 4 Most frequent AEs during repeated tegaserod treatment (ZENSAA [Tack et al 2005]), regardless of study drug
relationship
First treatment Repeated treatment
a
Tegaserod (n=2132)  Placebo (n=525)  Tegaserod (n=487) Placebo (n=494) 
n (%) n (%) n (%) n (%)
Headache 118 (5.5) 26 (5.0) 20 (4.1) 18 (3.6)
Diarrhea 81 (3.8)b 3 (0.6) 9 (1.8)c 2 (0.4)
Abdominal pain  48 (2.3) 13 (2.5) 5 (1.0) 6 (1.2)
Nausea 47  (2.2) 6 (1.1) 2 (0.4) 2 (0.4)
Nasopharyngitis 46  (2.2) 8 (1.5) 6 (1.2) 5 (1.0)
Influenza 24 (1.1) 7 (1.3) 1 (0.2) 2 (0.4)
Abdominal pain (upper) 23 (1.1) 3 (0.6) 3 (0.6) 2 (0.4)
Back pain 20 (0.9) 8 (1.5) 5 (1.0) 5 (1.0)
Dyspepsia 11 (0.5) 5 (1.0) 2 (0.4) 2 (0.4)
Urinary tract infection 11 (0.5) 6 (1.1) 5 (1.0) 3 (0.6)
Dysmenorrhea 11 (0.5) 3 (0.6) 2 (0.4) 5 (1.0)
Note: 
aRegardless of relationship to study drug; Includes only first treatment tegaserod patients who received repeated treatment; 
bp<0.0001; 
dp=0.04, tegaserod vs
placebo. Copyright © 2005. Reproduced with permission from BMJ from Tack J, Müller-Lissner S, Bytzer P, et al. 2005. A randomised controlled trial assessing the
efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation (IBS-C). Gut, 54:1707-13.
Figure 5 Adverse events (≥0.5%) leading to discontinuation in pivotal phase III
trials of tegaserod. Pooled data from Studies 1, 2 and 3 (Müller-Lissner et al
2001; Leftkowitz et al 1999; Novick et al 2002; Novartis, Data on file).
Note: *p<0.05 vs placebo.
Abbreviations: reprod, reproductive.Therapeutics and Clinical Risk Management 2007:3(1) 116
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profile and is not associated with any clinically significant
cardiac abnormalities. In particular, no alterations of ECG
parameters including QT-interval measurements have been
observed (Morganroth et al 2002).
Special safety considerations:
abdominal and pelvic surgery
Patients with IBS have a relatively high incidence of
abdominal/pelvic surgeries. For example, they are twice as
likely to undergo a cholescystectomy and four times more
likely to undergo appendectomy than healthy people (Hasler
and Schoenfeld 2003). In the US, prescribing information
for tegaserod notes that trials in IBS-C patients demonstrated
an increase in abdominal surgeries in tegaserod (0.3%)
compared with placebo (0.2%) patients, primarily due to
more cholecystectomies (0.17% and 0.06%, respectively).
The FDA specified that tegaserod is contraindicated in
patients with gallbladder disease, suspected sphincter of oddi
dysfunction, or abdominal adhesions. However, a recent
expert analysis of almost 10 000 patients in tegaserod clinical
trials found the incidence of abdominal/pelvic surgery cases,
including cholescystectomy, was comparable in tegaserod-
and placebo-treated patients (Schoenfeld 2004), and there
is no evidence that tegaserod has an effect on gallbladder
or sphincter of oddi function in healthy women or those
with IBS-C (Fisher et al 2003, 2004).
Special safety considerations:
pregnancy and breast feeding
Pregnancy was investigated in preclinical studies of
tegaserod in rats and rabbits at 90 and 360 times the human
dose of 6 mg bid, respectively. No harmful effects of
tegaserod were reported on pregnancy, embryonic or fetal
development, parturition or postnatal development (Appel-
Dingemanse 2002). Pregnancy was an exclusion factor in
the tegaserod clinical trial program, and all participating
women of child-bearing age were required to use a medically
approved method of contraception. Despite this, there were
35 (0.43%) pregnancies in tegaserod and 18 (0.40%)
pregnancies in placebo groups. Although these patients
withdrew from the studies as protocol violators, there was
no indication that tegaserod had a detrimental effect on
pregnancy or fetal development (Novartis. Data on file).
However, as no controlled studies of tegaserod have been
performed in pregnant women, its use during pregnancy is
not recommended.
Studies in lactating rats revealed that following oral
administration of tegaserod, levels of the drug were
approximately three-fold higher in milk than in plasma. This
suggests that a suckling infant will ingest tegaserod via
breast milk. Consequently, it is recommended that tegaserod
is not prescribed to women who are breast-feeding.
Drug–drug interactions and special
patient populations
The liver and kidneys play an important role in eliminating
tegaserod from the body. Tegaserod can be metabolized by
hepatic cytochrome P450 isozymes (CYP P450) or excreted
in urine and feces (Appel-Dingemanse 2002). Other drugs
are also metabolized by CYP P450, but there is no evidence
of drug–drug interactions between tegaserod and such drugs,
including theophylline (Zhou, Khalilieh, et al 2001),
dextromethorphan (Kalbag et al 2000), digoxin (Zhou,
Horowitz, et al 2001), warfarin (Ledford et al 2000), oral
contraceptives (Zhou et al 2000), or antidepressants (Vickers
et al 2001; Appel-Dingemanse 2002). These findings
indicate that tegaserod can be safely administered alongside
these commonly used drugs, with no need for dosage
adjustments.
Due to the involvement of the liver and kidneys in the
metabolism and excretion of tegaserod, the effects of
tegaserod in patients with hepatic and renal disease were
studied. Results showed that plasma concentrations of
tegaserod in patients with mild-to-moderate liver disease,
mild-to-moderate renal impairment, and in patients requiring
renal dialysis were comparable with levels in healthy
controls. Therefore, dose-adjustment of tegaserod is not
required in these patients (Zhou et al 1999; Appel-
Dingemanse 2002).
Concluding remarks
The efficacy and safety of tegaserod as a treatment for IBS-
C have been extensively investigated. Data from
randomized, placebo-controlled trials conducted in
numerous countries suggest that compared with placebo,
tegaserod provides rapid, sustained, and statistically
significant relief of overall IBS symptoms as well as
individual symptoms of abdominal pain/discomfort,
bloating, and constipation. These effects are also observed
during repeat treatment, which is important given the chronic
and recurring nature of IBS symptoms. The improvements
in IBS symptoms observed with tegaserod in comparison
with placebo are within the range observed with otherTherapeutics and Clinical Risk Management 2007:3(1) 117
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serotonergic agents. Moreover, efficacy has been confirmed
in open-label trials performed in real-life clinical settings,
thereby reflecting the response to treatment physicians may
observe in their patients. Tegaserod is associated with
significant improvements in patients’ QoL and work
productivity and is well tolerated, including over long-term
and repeated treatments. Diarrhea, the only AE consistently
associated with tegaserod therapy, is generally mild, of short
duration, and resolved without therapy. Overall, tegaserod
provides significant improvements for patients with IBS-
C, without compromising safety. Thus, it can be regarded
as an appropriate treatment option from the current agents
available for IBS-C.
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